Literature DB >> 21346683

Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age.

Pierre van Damme1, Froukje Kafeja, Marie Van Der Wielen, Maarten Leyssen, Jeanne-Marie Jacquet.   

Abstract

Long-term persistence of antibodies against hepatitis A and B (anti-HAV and anti-HBs) were evaluated in 1- to 11-year-old children following 2 doses (0, 6 months) of hepatitis A and B vaccine. Ten years postvaccination, all subjects were anti-HAV seropositive (≥15 mIU/mL), 81.7% had anti-HBs antibody concentrations ≥10 mIU/mL. All subjects with anti-HBs concentrations <10 mIU/mL, mounted a vigorous anamnestic response to an HBV vaccine challenge dose indicating the presence of immunologic memory against hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346683     DOI: 10.1097/INF.0b013e3182138296

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  3 in total

1.  Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children.

Authors:  Gregory A Raczniak; Timothy K Thomas; Lisa R Bulkow; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon
Journal:  Vaccine       Date:  2013-03-05       Impact factor: 3.641

2.  Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.

Authors:  Gregory A Raczniak; Lisa R Bulkow; Michael G Bruce; Carolyn L Zanis; Richard L Baum; Mary M Snowball; Kathy K Byrd; Umid M Sharapov; Thomas W Hennessy; Brian J McMahon
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

Review 3.  Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.

Authors:  Christian Herzog; Koen Van Herck; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.